HARMONY BIOSCIENCES

Harmony Biosciences Q1 2022 Financial and Business Update

May 3, 2022

Legal Disclaimer

This presentation includes forward-looking statements within the meaning of the Private Securities Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Holdings, Inc.'s (the "Company") future financial position, business strategy and plans and objectives of management for future operations, should be considered forward-looking statements. Forward-looking statements use words like "believes," "plans," "expects," "intends," "will," "would," "anticipates," "estimates," and similar words or expressions in discussions of the Company's future operations, financial performance or the Company's strategies. These statements are based on current expectations or objectives that are inherently uncertain, especially in light of the Company's limited operating history. These and other important factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 28, 2022 and its other filings with the SEC could cause actual results to differ materially and adversely from those indicated by the forward-looking statements made in this presentation. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.

This presentation includes information related to market opportunity as well as cost and other estimates obtained from internal analyses and external sources. The internal analyses are based upon management's understanding of market and industry conditions and have not been verified by independent sources. Similarly, the externally sourced information has been obtained from sources the Company believes to be reliable, but the accuracy and completeness of such information cannot be assured. Neither the company, nor any of its respective officers, directors, managers, employees, agents, or representatives, (i) make any representations or warranties, express or implied, with respect to any of the information contained herein, including the accuracy or completeness of this presentation or any other written or oral information made available to any interested party or its advisor (and any liability therefore is expressly disclaimed), (ii) have any liability from the use of the information, including with respect to any forward-looking statements, or (iii) undertake to update any of the information contained herein or provide additional information as a result of new information or future events or developments.

Harmony's Strategy for Growth



Q1 2022 WAKIX® Net Revenue Performance

Q1 2022 Net Revenue of $85.3M

1Q21	4Q21	1Q22	Δ 1Q22 vs. 4Q21	Δ 1Q22 vs. 1Q21
$59.7	$91.2	$85.3	(6%)	43%

- 43% growth Q1 2022 vs. Q1 2021
- Surpassed $500M in cumulative net revenue – achieved in less than 2 ½ years since launch

Driving Growth Through Our Launch For WAKIX
Q1 2022 Performance

Wakix® pitolisant tablets

>70% In-Person Access to HCPs

Patient Outreach Programs & Support

~3,900 Average # of WAKIX Patients

Healthcare Professional Educational Initiatives

Continued Growth in Depth & Breadth of Prescriber Base

Managed Care Education & Outreach

>80% U.S. Covered Lives With Formulary Access

INTUNE Study:
Phase 3 Registrational Trial of Pitolisant in Idiopathic Hypersomnia



Trial Design:

- Double-blind, placebo-controlled, randomized withdrawal study in patients with IH ≥18 years old
- ~200 patients to be enrolled into open-label dose optimization phase; responders will subsequently be entered into the randomized withdrawal phase
- ~60 - 80 clinical trial sites in the US

Objectives:

- Primary objective: to evaluate the safety and efficacy of pitolisant compared with placebo in treating EDS in patients with IH ≥18 years old
- Secondary objectives: to assess the impact of pitolisant on overall symptoms of IH, patient impression of overall change in their IH, investigator assessment of overall IH severity, functional status and activities of daily living, sleep-related impairment, sleep inertia, and cognitive function

IH=Idiopathic Hypersomnia; ESS=Epworth Sleepiness Scale; EDS=Excessive Daytime Sleepiness

Harmony Development Pipeline



1. Includes New Drug Applications and supplemental New Drug Applications.
2. Bioprojet conducted pediatric narcolepsy trial

HBS-102: Preclinical POC Study in PWS

- Melanin Concentrating Hormone (MCH) neurons are located in the hypothalamus and function as a key control center of feeding behavior and energy metabolism
- HBS-102 is an MCH receptor-1 (MCHR1) antagonist and this class of compounds has been shown to mediate the activity of MCH neurons
- Preclinical POC study planned to assess the effects of the MCHR1 antagonist HBS-102 on hyperphagia, weight gain and other metabolic parameters in a preclinical model (SNORD 116 KO mouse model) of PWS



Sargent, B.J., Moore, N.A. (2009) New Central Targets for the Treatment of Obesity. *British Journal of Clinical Pharmacology*. 68 852-860.

Q1 2022 Financial Highlights

(In millions, USD)

Net Product Revenues



Non-GAAP Adjusted Net Income(1)



Strong Operating Performance

Growth in Net Product Revenues and Non-GAAP Adjusted Net Income(1)

1. Non-GAAP Adjusted Net Income= GAAP Net Income excluding non-cash interest expense, depreciation, amortization, stock-based compensation, other non-operating items and tax effect of these items

Q1 2022 Financial Summary

(In millions, USD)	Three Months Ended March 31,	
	2022	2021
Net Product Revenues	**$85.3**	**$59.7**
Cost of Product Sold	14.7	10.4
Total Operating Expenses	**$43.0**	**$34.7**
R&D Expense	7.6	4.7
S&M Expense	17.6	15.5
G&A Expense	17.9	14.5
Net Income	**$21.5**	**$7.4**
Cash & cash equivalents	**$224.5**	

Totals may not foot due to rounding

Q1 2022 GAAP vs Non-GAAP Reconciliation

(In millions, USD)	Three Months Ended March 31,	
	2022	2021
GAAP net income	**$21.5**	**$7.4**
Non-cash interest expense[1]	0.4	0.7
Depreciation	0.1	0.1
Amortization[2]	5.1	4.6
Stock-based compensation expense	4.9	3.3
Income tax effect related to Non-GAAP adjustments[3]	(0.9)	-
Non-GAAP adjusted net income	**$31.1**	**$16.0**
GAAP net income per diluted share	**$0.35**	**$0.13**
Non-GAAP adjusted net income per diluted share	**$0.51**	**$0.27**
Weighted average number of shares of common stock used in non-GAAP diluted per share	60,586,875	58,805,285

Totals may not foot due to rounding

1. Includes amortization of deferred finance charges
2. Includes amortization of intangible assets related to WAKIX
3. Calculated using the reported effective tax rate for the periods presented

HARMONY BIOSCIENCES

Thank You